Kayo Takeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kayo Takeda has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Shigeki Katakami
Department of Psychiatry The University of Osaka Graduate School of Medicine Suita Osaka Japan
3 shared publications - Yuto Satake
Department of Psychiatry The University of Osaka Graduate School of Medicine Suita Osaka Japan
3 shared publications - Daiki Taomoto
Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
2 shared publications - Hideki Kanemoto
Department of Psychiatry The University of Osaka Graduate School of Medicine Suita Osaka Japan
2 shared publications Kenji Yoshiyama
Department of Psychiatry The University of Osaka Graduate School of Medicine Suita Osaka Japan
2 shared publicationsManabu Ikeda
Department of Psychiatry The University of Osaka Graduate School of Medicine Suita Osaka Japan
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (9) , 2279-2290
123I−FP−CIT uptake and behavioral disinhibition in the frontotemporal dementia spectrum: an exploratory DAT−SPECT study
Behavioral disinhibition is a core feature of behavioral variant frontotemporal dementia (bvFTD) and occurs across related FTD-spectrum presentations. Serotonergic dysfunction may contribute to behavioral dysregulation; therefore, we primarily examined dorsal raphe (DR)-centered midbrain ¹²³I-FP-CIT uptake as an indirect extrastriatal signal that may partly reflect serotonin transporter-related binding. Because striatal dopaminergic circuits support reward learning, behavioral inhibition, and context-dependent behavioral updating, striatal uptake was examined exploratorily. This retrospective exploratory study included 21 patients within the FTD spectrum who underwent Neuropsychiatric Inventory (NPI) assessment, magnetic resonance imaging, and ¹²³I-FP-CIT single-photon emission computed tomography within a 3-month window. The primary outcome was the NPI disinhibition score. DR-centered midbrain and striatal specific uptake ratios (SURs) were calculated using the cerebellum as the reference region. Age- and sex-adjusted quasi-Poisson models with a log link were fitted. DR-centered midbrain SUR was not significantly associated with disinhibition in the primary model (β = −1.027, p = 0.353). In the exploratory model, higher striatal SUR was nominally associated with lower disinhibition scores (β = −0.438, p = 0.022). The negative direction of the striatal association was generally preserved across sensitivity analyses, although nominal significance was not retained in all models. DR-centered midbrain SUR was not significantly associated with behavioral disinhibition in this small FTD-spectrum cohort. Lower striatal SUR showed a directionally consistent but sensitivity-dependent nominal association with greater disinhibition. This hypothesis-generating finding may reflect broader frontostriatal disease burden, striatal neurodegeneration, parkinsonian-spectrum overlap, or partial-volume effects and does not establish a disinhibition-specific dopaminergic mechanism.
- 21 August 2026
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (9) , 2279-2290
Open Access123I−FP−CIT uptake and behavioral disinhibition in the frontotemporal dementia spectrum: an exploratory DAT−SPECT study
Behavioral disinhibition is a core feature of behavioral variant frontotemporal dementia (bvFTD) and occurs across related FTD-spectrum presentations. Serotonergic dysfunction may contribute to behavioral dysregulation; therefore, we primarily examined dorsal raphe (DR)-centered midbrain ¹²³I-FP-CIT uptake as an indirect extrastriatal signal that may partly reflect serotonin transporter-related binding. Because striatal dopaminergic circuits support reward learning, behavioral inhibition, and context-dependent behavioral updating, striatal uptake was examined exploratorily. This retrospective exploratory study included 21 patients within the FTD spectrum who underwent Neuropsychiatric Inventory (NPI) assessment, magnetic resonance imaging, and ¹²³I-FP-CIT single-photon emission computed tomography within a 3-month window. The primary outcome was the NPI disinhibition score. DR-centered midbrain and striatal specific uptake ratios (SURs) were calculated using the cerebellum as the reference region. Age- and sex-adjusted quasi-Poisson models with a log link were fitted. DR-centered midbrain SUR was not significantly associated with disinhibition in the primary model (β = −1.027, p = 0.353). In the exploratory model, higher striatal SUR was nominally associated with lower disinhibition scores (β = −0.438, p = 0.022). The negative direction of the striatal association was generally preserved across sensitivity analyses, although nominal significance was not retained in all models. DR-centered midbrain SUR was not significantly associated with behavioral disinhibition in this small FTD-spectrum cohort. Lower striatal SUR showed a directionally consistent but sensitivity-dependent nominal association with greater disinhibition. This hypothesis-generating finding may reflect broader frontostriatal disease burden, striatal neurodegeneration, parkinsonian-spectrum overlap, or partial-volume effects and does not establish a disinhibition-specific dopaminergic mechanism.
- Open Access
- 10 August 2026
- Published by Wiley in Psychogeriatrics
- Vol. 26 (5) , e70205
Progression to Dementia in Very Late‐Onset Schizophrenia‐Like Psychosis Stratified by A lzheimer's Disease and L ewy Body Disease Biomarkers: A Retrospective Cohort Study
Background: Very late‐onset schizophrenia‐like psychosis (VLOSLP) is clinically heterogeneous, and its relationship with dementia‐related neurodegenerative disease remains unresolved. We examined whether Alzheimer's disease (AD) and Lewy body disease (LBD) biomarker status were associated with dementia progression in VLOSLP. Methods: We retrospectively identified patients who visited the University of Osaka Hospital between January 2018 and December 2023 and met criteria for VLOSLP. Twenty‐two participants with AD and/or LBD biomarker data and at least one follow‐up assessment within 775 days were classified as biomarker‐negative (BMs‐neg; n = 7) or biomarker‐positive (BMs‐pos; n = 15). Group comparisons were performed using Mann–Whitney U tests and Fisher's exact tests. Results: The BMs‐pos group showed older onset age and lower memory scores than the BMs‐neg group. Dementia progression was more frequent in the BMs‐pos group than in the BMs‐neg group, although the difference was not statistically significant (8/15 [53.3%] vs. 1/7 [14.3%]; p = 0.165; odds ratio 6.31; 95% CI 0.55–353.18). Five of eight participants with AD biomarker positivity progressed to AD dementia. Three of seven participants with LBD biomarker positivity progressed to dementia, including two diagnosed with dementia with Lewy bodies. Follow‐up MMSE, CDR, and CDR‐SB scores differed significantly between groups. Conclusions: AD and/or LBD biomarker‐positive VLOSLP may be associated with greater dementia progression and cognitive decline, although findings should be interpreted cautiously given the small sample size and retrospective design. These results support the clinical value of considering neurodegenerative biomarkers when evaluating the prognosis and underlying pathology of VLOSLP.
- 10 August 2026
- Published by Wiley in Psychogeriatrics
- Vol. 26 (5) , e70205
Open AccessProgression to Dementia in Very Late‐Onset Schizophrenia‐Like Psychosis Stratified by A lzheimer's Disease and L ewy Body Disease Biomarkers: A Retrospective Cohort Study
Background: Very late‐onset schizophrenia‐like psychosis (VLOSLP) is clinically heterogeneous, and its relationship with dementia‐related neurodegenerative disease remains unresolved. We examined whether Alzheimer's disease (AD) and Lewy body disease (LBD) biomarker status were associated with dementia progression in VLOSLP. Methods: We retrospectively identified patients who visited the University of Osaka Hospital between January 2018 and December 2023 and met criteria for VLOSLP. Twenty‐two participants with AD and/or LBD biomarker data and at least one follow‐up assessment within 775 days were classified as biomarker‐negative (BMs‐neg; n = 7) or biomarker‐positive (BMs‐pos; n = 15). Group comparisons were performed using Mann–Whitney U tests and Fisher's exact tests. Results: The BMs‐pos group showed older onset age and lower memory scores than the BMs‐neg group. Dementia progression was more frequent in the BMs‐pos group than in the BMs‐neg group, although the difference was not statistically significant (8/15 [53.3%] vs. 1/7 [14.3%]; p = 0.165; odds ratio 6.31; 95% CI 0.55–353.18). Five of eight participants with AD biomarker positivity progressed to AD dementia. Three of seven participants with LBD biomarker positivity progressed to dementia, including two diagnosed with dementia with Lewy bodies. Follow‐up MMSE, CDR, and CDR‐SB scores differed significantly between groups. Conclusions: AD and/or LBD biomarker‐positive VLOSLP may be associated with greater dementia progression and cognitive decline, although findings should be interpreted cautiously given the small sample size and retrospective design. These results support the clinical value of considering neurodegenerative biomarkers when evaluating the prognosis and underlying pathology of VLOSLP.
- Open Access
- 10 February 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (1)
Associations of living alone and loneliness with neuropsychiatric symptoms in individuals with mild cognitive impairment: A retrospective cross‐sectional study
Aim: Living alone and loneliness are recognized risk factors for neuropsychiatric symptoms in older adults. However, the distinct of the objective condition of living alone and subjective loneliness on specific neuropsychiatric symptoms in individuals with mild cognitive impairment (MCI) remains unclear. Methods: In this retrospective study, we analyzed data from 312 older adults with MCI (74 living alone and 238 living with family) who attended a university psychiatry clinic. Neuropsychiatric symptoms and subjective loneliness were assessed using the Neuropsychiatric Inventory and the UCLA Loneliness Scale, respectively. Living arrangement (living alone vs. living with family) was recorded. Negative binomial regression with a log link function examined associations of depression, anxiety, delusions, and hallucinations with living alone and loneliness, adjusting for potential confounders. Furthermore, sensitivity analyses were performed by excluding variables with highly unbalanced distributions. Results: Patients living alone showed significantly higher delusions, hallucinations, and disinhibition scores than those living with family, whereas apathy scores were significantly lower. Multivariate analyses showed that loneliness, but not living alone, was significantly associated with depression and anxiety. Delusions were significantly associated with both loneliness and living alone. In contrast, no significant associations were found between hallucinations and either living alone or loneliness. The significant associations for all neuropsychiatric symptoms were maintained in the sensitivity analysis, except for hallucinations. Conclusion: Neuropsychiatric symptoms in individuals with MCI show differential associations with loneliness and living alone. These findings suggest that useful non‐pharmacological interventions may differ depending on the symptoms.
- 10 February 2026
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 5 (1)
Open AccessAssociations of living alone and loneliness with neuropsychiatric symptoms in individuals with mild cognitive impairment: A retrospective cross‐sectional study
Aim: Living alone and loneliness are recognized risk factors for neuropsychiatric symptoms in older adults. However, the distinct of the objective condition of living alone and subjective loneliness on specific neuropsychiatric symptoms in individuals with mild cognitive impairment (MCI) remains unclear. Methods: In this retrospective study, we analyzed data from 312 older adults with MCI (74 living alone and 238 living with family) who attended a university psychiatry clinic. Neuropsychiatric symptoms and subjective loneliness were assessed using the Neuropsychiatric Inventory and the UCLA Loneliness Scale, respectively. Living arrangement (living alone vs. living with family) was recorded. Negative binomial regression with a log link function examined associations of depression, anxiety, delusions, and hallucinations with living alone and loneliness, adjusting for potential confounders. Furthermore, sensitivity analyses were performed by excluding variables with highly unbalanced distributions. Results: Patients living alone showed significantly higher delusions, hallucinations, and disinhibition scores than those living with family, whereas apathy scores were significantly lower. Multivariate analyses showed that loneliness, but not living alone, was significantly associated with depression and anxiety. Delusions were significantly associated with both loneliness and living alone. In contrast, no significant associations were found between hallucinations and either living alone or loneliness. The significant associations for all neuropsychiatric symptoms were maintained in the sensitivity analysis, except for hallucinations. Conclusion: Neuropsychiatric symptoms in individuals with MCI show differential associations with loneliness and living alone. These findings suggest that useful non‐pharmacological interventions may differ depending on the symptoms.